Hepatitis B and C among blood donors in tartous city, syria. A retrospective study

Hamdane, Houssam; Harfouch, Rim

doi:10.5958/0974-360x.2021.00080.9

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This heterogeneity in social, cultural and educational factors is expected to determine the regional prevalence of infectious diseases. In agreement with our findings, a recent study conducted has reported a prevalence of 0.56% for HBV in blood donors at the coastal city of Tartus in 2017 ( 20 ). Similar to the capital Damascus, the Syrian coast has received a massive arrival of displaced people during the Syrian conflict, and the comparable frequencies of HBV seropositivity at Tartus blood transfusion center and Damascus University Blood Center may suggest homogeneity of blood donor populations at both centers.…”

Section: Discussionsupporting

confidence: 94%

“…Here, we report an apparent association between higher HBV prevalence and older ages ≥26, and additionally, starting in 2012 through 2021, remarkably lower HBV prevalence was obvious in blood donors of the youngest age group 18–25 years old, who are expected to have received the HBV vaccine ( Figure 3C ). This observation was consistent with results obtained from Blood Transfusion Center of Tartus ( 20 ) and among multi-transfused Patients with Hemoglobinopathy ( 17 ). Moreover, the deterioration of the immune system, termed immunosenescence, is related to aging, which makes older people more vulnerable to infections ( 33 ).…”

Section: Discussionsupporting

confidence: 93%

“…Our comprehensive analysis of blood donors' records at the Damascus University Blood Center revealed that females constituted only 17.73% of all donors; a percentage close to that reported from a similar study in Tartus (17.69%) ( 20 ), and which is nearly half of the global percentage (33%). On the other hand, when compared with Eastern Mediterranean countries, Syria ranks among the upper-middle countries in terms of women's participation in blood donations, as the region has a median of 6% female blood donors with substantial between-country differences (range from 0.4 to 31%).…”

Section: Discussionsupporting

confidence: 75%

“…With regard to HCV, data published by the Syrian MoH in 2004 revealed a 2.8% seropositivity of HCV in the general population, but a lower HCV prevalence in Syrian blood donors whose seropositivity fluctuated between 0.46 and 0.4% within the time frame (between 2003 and 2014) of that study ( 19 ). Similarly, data from Tartus Blood Transfusion Center reported a 0.48% HCV prevalence in 2017 ( 20 ). Interestingly, our data supports similar trends at Damascus University Blood Center with 0.52% overall prevalence rate.…”

Section: Discussionmentioning

confidence: 95%

“…In 2014, the recorded prevalence rates of HBV and HCV at the national blood banks were 1.1 and 0.4%, respectively ( 19 ). A recent study carried out in the coastal city of Tartus reported seropositivity rates in local blood donors of 0.56 and 0.48% for HBV and HCV, respectively ( 20 ).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Seroprevalence and trends of hepatitis B virus, hepatitis C virus and human immunodeficiency virus in Syrian blood donors at Damascus University Blood Center between 2004 and 2021

Alassad,

Al Rahwanji,

Yousfan

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

IntroductionSeroprevalence of transfusion-transmitted viral infections (TTVIs) is a valuable indicator for assessing blood safety, population health and health system performance in the times of peace and conflicts. Only scarce information is available on the impact of the decade-long violent conflict on the prevalence of TTVIs in Syria. Moreover, hepatitis B vaccine was introduced to the national vaccination program in 1993; however, no data is available on the vaccine effectiveness.MethodsIn this retrospective cross-sectional study, we compiled the screening results for major TTVIs, namely hepatitis B virus (HBV), hepatitis C virus (HCV), and human immuno-deficiency virus (HIV), of volunteer donors at Damascus University Blood Center from May 2004 to October 2021. Prevalence was expressed in percentages for the entire study group and subgroups. Chi-square test and linear regression were used to examine the differences and describe trends in prevalence, respectively, based on demographic characteristics (i.e., age and gender) and time. P-value of <0.005 was considered statistically significant.ResultsOf the total 307,774 donors (82.27% males, median age 27 years), 5,929 (1.93%) had serological evidence of at least one TTVI, and 26 (0.0085%) had multiple infections. The lowest prevalence (1.09%) was detected in donors aged 18–25 years old, and a higher prevalence (2.05%) was evident in males in comparison with females (1.38%). The seroprevalence of HBV, HCV, and HIV was 1.18, 0.52, and 0.23%, respectively. Trend analyses revealed a significant regression in HBV and HIV prevalence from 2011 to 2021. HBV seropositivity depicted a temporal decline by ~80%, from 0.79% in 2011 to 0.16% in 2021 in those born in 1993 and thereafter.DiscussionThe seroprevalence of HBV, HIV, and to a lesser extent HCV dropped over the study 18-year period. Possible explanations may include implementation of the HBV vaccine, robust national health system, conservative sociocultural values, and isolation.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 75%

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Seroprevalence and trends of hepatitis B virus, hepatitis C virus and human immunodeficiency virus in Syrian blood donors at Damascus University Blood Center between 2004 and 2021

Alassad,

Al Rahwanji,

Yousfan

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

Status of HBeAg in association with other baseline tests in Iraqi patients with CHB

Alheany

Abdullah

2022

RJPT

View full text Add to dashboard Cite

Chronic Hepatitis B(CHB) is a serious sequel after Hepatitis B Virus infection, although the rate of chronicity is inverse with age but it may be associated with a significant proportion of deaths related to cirrhosis and liver cancer. HBV serology and measurement of hepatocytic enzymes with viral load can predict disease prognosis and response to treatment. HBeAg refers to a high viral replication and associated with more infectivity to others. This study aimed to determine the impact of HBeAg status in chronically infected patients on various baseline tests. A total of 90 patients with CHB infection who were included in this study. Several standardized measures used for liver function tests, viral load and hepatitis B serological markers. HBeAg was negative in 81/90 (90%) patients and positive in 9/90(10%). There was significant association between HBeAg serostatus and HBV-DNA viral load (p=0.042), as more than half of the cases (55.6%) had high levels of HBV serum DNA (≥2000 IU/ml) and positive HBeAg compared to 24.7% of cases with negative HBeAg. HBeAg seroconversion was not associated with liver function tests, modes of transmission, duration of chronicity, marital status, gender and age. We concluded that HBeAg sero-negativity among the studied cases can predict the inactive or reactive phase of chronic hepatitis B, if the latter is associated with high viral loads, so that further studies are needed to find out associated precore mutants.

show abstract

Combined Interferon-Antiviral therapy effectiveness against Hepatitis B viral infection in Babylon Province

Al-Shimmery

Bayram

Mammori

et al. 2022

RJPT

View full text Add to dashboard Cite

Hepatitis can be defined as one of the liver’s inflammations that might be caused via viral infections, toxins, drugs and alcohol. The hepatitis via viral infection can be classified according to the type of viral strain and symptom into (A, B, C, D, E), the Hepatitis B is specified as one of the dangerous diseases resulting from a virus that is infecting the liver and has the ability of causing life-long infection, liver failure, liver cancer, cirrhosis (liver scarring) and death. The current work is carried out for evaluating the interferon as well as antiviral treatment effect on the viral load and viral activity among certain group of Hepatitis B virus infected patients enrolled to GIT and liver center in Merjan Medical City using Real time PCR for viral load and viral copy number determination. The results show that the all recorded cases in GIT center about (3612 hepatitis virus at both B and C), 2226 for HBV and 1386 for HCV, only 566 HBV patients was analysis by PCR around the year 2016. The males were high significant than females in hepatitis B infections. The north area of Babylon province had higher percentage than south and middle areas. Low activity of treatment protocol was mentioned on HBV infected patients, where (38.62 %) of patients had final outcome as undetectable viral load after treatment with combined interferon and oral anti–viral drugs. Conclusion: was that the combination treatment of immunological derivative and oral treatment more effective than single treatment used in HBV infection.

show abstract

Hepatitis B and C among blood donors in tartous city, syria. A retrospective study

Cited by 3 publications

References 0 publications

Seroprevalence and trends of hepatitis B virus, hepatitis C virus and human immunodeficiency virus in Syrian blood donors at Damascus University Blood Center between 2004 and 2021

Seroprevalence and trends of hepatitis B virus, hepatitis C virus and human immunodeficiency virus in Syrian blood donors at Damascus University Blood Center between 2004 and 2021

Status of HBeAg in association with other baseline tests in Iraqi patients with CHB

Combined Interferon-Antiviral therapy effectiveness against Hepatitis B viral infection in Babylon Province

Contact Info

Product

Resources

About